Humanized Antibody Amyloid-Beta Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating amyloidosis, particularly Alzheimer's disease and age-related macular degeneration, are inadequate as they fail to effectively prevent or reverse the formation of amyloid plaques and do not provide significant long-term benefits, with existing treatments having modest effects and side effects such as gastrointestinal dysfunction and liver toxicity.
Innovation Solution
Development of highly specific and effective chimeric or humanized antibodies that recognize and bind to specific epitopes on the β-amyloid protein, inhibiting its aggregation and dissolving existing plaques, thereby reducing the amyloid burden in the brain and retina.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for amyloidosis are used, then some therapeutic effect is achieved, but the effects are only modest and side effects occur such as gastrointestinal dysfunction and liver toxicity
Solution Approach 1:
The patent modifies the molecular structure of antibodies by humanizing them - changing the parameters of the antibody composition from murine to human sequences. This structural parameter change maintains the therapeutic ability to bind amyloid-beta while eliminating the immunogenicity that causes side effects like gastrointestinal dysfunction and liver toxicity.
Solution Approach 2:
The patent uses humanized antibodies as an intermediary between the immune system and amyloid-beta plaques. These humanized antibodies serve as a bridge that provides therapeutic efficacy without triggering the harmful immune responses that occur with fully murine antibodies, thus mediating between effectiveness and safety.
2Reliability
If murine antibodies are used to target amyloid-beta, then binding affinity is achieved, but immunogenicity causes adverse immune responses in humans
Solution Approach 1:
The patent changes the sequence parameters of the antibody from murine to humanized sequences while maintaining the complementarity determining regions (CDRs) that provide binding affinity. This parameter change in the antibody's amino acid sequence eliminates immunogenicity while preserving the ability to bind amyloid-beta with high affinity.
Solution Approach 2:
The patent segments the antibody structure into different functional regions: the CDRs that provide binding affinity are retained from the murine antibody, while the framework regions are replaced with human sequences. This segmentation allows the antibody to maintain binding functionality while eliminating the immunogenic portions.
Data Source
AI summary
The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.